Jafron Biomedical Co

Jafron Biomedical Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co (300529.SZ) as of Oct 21, 2026 is 13.67 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 19.42 % — a change of -29.59% (lower).

EBIT/Assets

13.67 %

YoY

-29.59%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co is 2025 13.67 % . Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co was 2024 19.42 % . It decreases by -29.59% lower compared to the previous year.

The Jafron Biomedical Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
23.21 CNY
Jan 1, 2019
27.27 CNY
Jan 1, 2020
32.78 CNY
Jan 1, 2021
29.48 CNY
Jan 1, 2022
19.02 CNY
Jan 1, 2023
9.81 CNY
Jan 1, 2024
19.42 CNY
Jan 1, 2025
13.67 CNY
The Jafron Biomedical Co EBIT/Assets history
YEAREBIT/AssetsYoY
13.67 %-29.59%
19.42 %+97.93%
9.81 %-48.41%
19.02 %-35.49%
29.48 %-10.07%
32.78 %+20.19%
27.27 %+17.49%
23.21 %+19.13%
19.48 %+8.86%
17.90 %-46.88%
33.69 %+4.35%
32.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co is 13.67 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co changed from 19.42 % to 13.67 %, representing a -29.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co